Nur Afiqah Mohamad1, Vasudevan Ramachandran1, Patimah Ismail2, Hazlita Mohd Isa3, Yoke Mun Chan1,4, Nor Fariza Ngah5, Norshakimah Md Bakri1, Siew Mooi Ching6, Fan Kee Hoo7, Wan Aliaa Wan Sulaiman7. 1. Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Selangor DE 43400, Malaysia. 2. Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor DE 43400, Malaysia. 3. Department of Ophthalmology, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur 56000, Malaysia. 4. Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor DE 43400, Malaysia. 5. Department of Ophthalmology, Hospital Selayang, Lebuhraya Selayang-Kepong, Batu Caves 68100, Malaysia. 6. Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor DE 43400, Malaysia. 7. Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor DE 43400, Malaysia.
Abstract
AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. METHODS: Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded. RESULTS: The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (P<0.001) while PCV was associated with more likely to have received PDT (P<0.001) and PDT combined with ranibizumab therapy (P<0.001). CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.
AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal diseasepatients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. METHODS: Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded. RESULTS: The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (P<0.001) while PCV was associated with more likely to have received PDT (P<0.001) and PDT combined with ranibizumab therapy (P<0.001). CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.
Authors: Sannapaneni Krishnaiah; Taraprasad Das; Praveen K Nirmalan; Rishita Nutheti; Bindiganavale R Shamanna; Gullapalli N Rao; Ravi Thomas Journal: Invest Ophthalmol Vis Sci Date: 2005-12 Impact factor: 4.799
Authors: U Schmidt-Erfurth; J Miller; M Sickenberg; A Bunse; H Laqua; E Gragoudas; L Zografos; R Birngruber; H van den Bergh; A Strong; U Manjuris; M Fsadni; A M Lane; B Piguet; N M Bressler Journal: Graefes Arch Clin Exp Ophthalmol Date: 1998-05 Impact factor: 3.117
Authors: David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2010-04-09 Impact factor: 12.079
Authors: Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz Journal: Graefes Arch Clin Exp Ophthalmol Date: 2005-10-20 Impact factor: 3.117
Authors: Nur Afiqah Mohamad; Vasudevan Ramachandran; Hazlita Mohd Isa; Yoke Mun Chan; Nor Fariza Ngah; Siew Mooi Ching; Fan Kee Hoo; Wan Aliaa Wan Sulaiman; Liyana Najwa Inche Mat; Mohd Hazmi Mohamed Journal: Hum Genomics Date: 2019-02-22 Impact factor: 4.639
Authors: Rituparna Ghoshal; Sharanjeet Sharanjeet-Kaur; Norliza Mohamad Fadzil; Somnath Ghosh; Nor Fariza Ngah; Roslin Azni Binti Abd Aziz Journal: Int J Environ Res Public Health Date: 2021-03-04 Impact factor: 3.390